A two-dose, non-live vaccine that rebuilds immune control of the dormant chickenpox virus. It prevents the great majority of shingles episodes and the lasting nerve pain that can follow, and protection remains substantial a decade later. Claims of less memory loss and fewer heart events remain unproven. Costs are one to three days of reaction after each dose. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Absolute lymphocyte count | 1.5–3.0 × 109/L | Predicts capacity to mount a helper T-cell response |
| Total immunoglobulin G (IgG) | 700–1600 mg/dL | Flags underlying antibody deficiency |
| High-sensitivity C-reactive protein (hs-CRP) | Below 1.0 mg/L, ideally below 0.5 mg/L | Marks active inflammation that argues for deferring a dose |
| Glycated hemoglobin (HbA1c) | 5.0–5.4% | Poor glycemic control raises shingles risk and weakens vaccine responses |
| 25-hydroxyvitamin D | 40–60 ng/mL (100–150 nmol/L) | Low status is associated with weaker vaccine responses |
| Anti-glycoprotein E immunoglobulin G | No established protective threshold; track change from the pre-vaccination value | Confirms an immune response was mounted |
| CD4+ T-cell count | Above 500 cells/µL | Determines whether vaccination should be timed differently |
Cadence: Baseline, symptom review at 7 days after each dose, a clinical check at 1 month after dose two, then a return to whatever annual or biannual panel is already in place